<?xml version="1.0" encoding="UTF-8"?>
<project>
  <language>en</language>
  <availableLanguages>en</availableLanguages>
  <rcn>242431</rcn>
  <id>190151672</id>
  <acronym>RESPIRE</acronym>
  <teaser>Palobiofarma is a Spanish biotech company with the ambition to develop new treatments for cancer and autoimmune diseases based on adenosine receptor modulation. Our compound PBF-680 is a first-in-class therapy with disease modifying effects in respiratory diseases like COPD...</teaser>
  <objective>Palobiofarma is a Spanish biotech company with the ambition to develop new treatments for cancer and autoimmune diseases based on adenosine receptor modulation. Our compound PBF-680 is a first-in-class therapy with disease modifying effects in respiratory diseases like COPD. Over 65M
        patients suffer from COPD, yet there are no approved therapies that target disease progression. PBF-680 is a unique molecule designed to specifically antagonise the Adenosine 1 Receptor (A1R). it has shown to be safe and well-tolerated in phase 1 trials and demonstrated to reduce pulmonary
        symptoms and inflammation in mild-to-moderate asthmatics in phase 2 trials. With funding from the EIC Accelerator, we will demonstrate efficacy in a phase 2 trial in COPD, a market with high unmet medical need. Proven clinical efficacy will be the major milestone to raise 30M (incl 15M EIC
        Equity) for a phase 3 trial, followed by an additional fund raising or IPO to independently reach market launch with PBF-680.</objective>
  <title>Development of the first oral disease-modifying treatment for chronic obstructive pulmonary disease (COPD)</title>
  <totalCost>3537295</totalCost>
  <ecMaxContribution>2476106.5</ecMaxContribution>
  <startDate>2022-01-01</startDate>
  <endDate>2024-06-30</endDate>
  <ecSignatureDate>2022-10-06</ecSignatureDate>
  <duration>30</duration>
  <status>CLOSED</status>
  <keywords>drug development,disease-modifying,adenosine,adenosine receptor 1 antagonist,inflammation,bronchoconstriction,COPD,oral anti-inflammatory drug,exacerbation prevention</keywords>
  <identifiers>
    <grantDoi>10.3030/190151672</grantDoi>
  </identifiers>
  <validation>
    <euroSciVoc>false</euroSciVoc>
  </validation>
  <sourceUpdateDate>2023-11-20 15:52:20</sourceUpdateDate>
  <contentCreationDate>2022-10-13 15:58:15</contentCreationDate>
  <contentUpdateDate>2022-10-13 15:58:07</contentUpdateDate>
  <lastUpdateDate>2025-09-19 14:49:07</lastUpdateDate>
  <relations>
    <associations>
      <article source="editorial" type="relatedArticle">
        <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
        <rcn>438639</rcn>
        <id>438639-development-of-therapy-for-chronic-obstructive-pulmonary-disease</id>
        <title>Development of therapy for chronic obstructive pulmonary disease</title>
        <contentUpdateDate>2023-03-13 18:10:01</contentUpdateDate>
        <relations>
          <categories>
            <category classification="collection" type="belongsTo">
              <language>en</language>
              <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
              <code>/projectDescription</code>
              <title>Project description</title>
              <description>Article: description of linked project written by editorial team</description>
              <displayCode>/Project description</displayCode>
            </category>
            <category classification="source" type="isProvidedBy">
              <language>en</language>
              <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
              <code>/editorial</code>
              <title>CORDIS Editorial</title>
              <description>Written by CORDIS</description>
              <displayCode>/CORDIS Editorial</displayCode>
            </category>
          </categories>
        </relations>
      </article>
      <call source="corda" type="relatedMasterCall">
        <rcn>55403</rcn>
        <title>HORIZON-EIC-2021-ACCELERATOROPEN-01</title>
        <identifier>HORIZON-EIC-2021-ACCELERATOROPEN-01</identifier>
      </call>
      <call source="corda" type="relatedSubCall">
        <rcn>55403</rcn>
        <title>HORIZON-EIC-2021-ACCELERATOROPEN-01</title>
        <identifier>HORIZON-EIC-2021-ACCELERATOROPEN-01</identifier>
      </call>
      <organization netEcContribution="2476106.5" totalCost="3537295" source="corda" order="1" ecContribution="2476106.5" terminated="false" sme="true" type="coordinator">
        <availableLanguages>en</availableLanguages>
        <rcn>1978359</rcn>
        <id>934979606</id>
        <vatNumber>ESB63998843</vatNumber>
        <legalName>PALO BIOFARMA SL</legalName>
        <address>
          <street>PG IND MOCHOLI PZ CEIN 2</street>
          <city>Mataro</city>
          <postalCode>31110</postalCode>
          <country>ES</country>
          <geolocation>42.7627828,-1.6341152</geolocation>
        </address>
        <relations>
          <categories>
            <category classification="organizationActivityType" type="relatedOrganizationActivityType">
              <language>en</language>
              <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
              <code>/PRC</code>
              <title>Private for-profit entities (excluding Higher or Secondary Education Establishments)</title>
              <displayCode>/Private for-profit entities (excluding Higher or Secondary Education Establishments)</displayCode>
            </category>
          </categories>
          <regions>
            <region type="relatedNutsCode">
              <name>Navarra</name>
              <rcn>242229376</rcn>
              <nutsCode>ES220</nutsCode>
              <parents>
                <region>
                  <name>Comunidad Foral de Navarra</name>
                  <rcn>242229416</rcn>
                  <nutsCode>ES22</nutsCode>
                  <parents>
                    <region>
                      <name>Noreste</name>
                      <rcn>242231848</rcn>
                      <nutsCode>ES2</nutsCode>
                      <parents>
                        <region>
                          <name>Spain</name>
                          <rcn>242387496</rcn>
                          <nutsCode>ES</nutsCode>
                          <euCode>ES</euCode>
                          <isoCode>ES</isoCode>
                        </region>
                      </parents>
                    </region>
                  </parents>
                </region>
              </parents>
            </region>
            <region type="relatedRegion">
              <name>Spain</name>
              <rcn>242387496</rcn>
              <nutsCode>ES</nutsCode>
              <euCode>ES</euCode>
              <isoCode>ES</isoCode>
            </region>
          </regions>
        </relations>
      </organization>
      <programme type="relatedLegalBasis" source="corda">
        <availableLanguages>en</availableLanguages>
        <rcn>705794</rcn>
        <id>HORIZON.3.1.2</id>
        <code>HORIZON.3.1.2</code>
        <frameworkProgramme>HORIZON</frameworkProgramme>
        <pga>HORIZON.3.1.2</pga>
        <title>The Accelerator</title>
        <parent>
          <programme>
            <rcn>705792</rcn>
            <code>HORIZON.3.1</code>
            <parent>
              <programme>
                <rcn>705791</rcn>
                <code>HORIZON.3</code>
                <parent>
                  <programme>
                    <rcn>705725</rcn>
                    <code>HORIZON</code>
                  </programme>
                </parent>
              </programme>
            </parent>
          </programme>
        </parent>
        <relations>
          <categories>
            <category classification="collection" type="belongsTo">
              <language>en</language>
              <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
              <code>/legalbasis</code>
              <title>Legal Basis</title>
              <description>Programme: Legal basis for research funding</description>
              <displayCode>/Legal Basis</displayCode>
            </category>
            <category classification="source" type="isProvidedBy">
              <language>en</language>
              <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
              <code>/corda</code>
              <title>CORDA</title>
              <description>RTD research data warehouse</description>
              <displayCode>/CORDA</displayCode>
            </category>
          </categories>
        </relations>
      </programme>
      <programme type="relatedLegalBasis" source="corda" uniqueProgrammePart="true">
        <availableLanguages>en</availableLanguages>
        <rcn>705792</rcn>
        <id>HORIZON.3.1</id>
        <code>HORIZON.3.1</code>
        <frameworkProgramme>HORIZON</frameworkProgramme>
        <pga>HORIZON.3.1</pga>
        <title>The European Innovation Council (EIC)</title>
        <parent>
          <programme>
            <rcn>705791</rcn>
            <code>HORIZON.3</code>
            <parent>
              <programme>
                <rcn>705725</rcn>
                <code>HORIZON</code>
              </programme>
            </parent>
          </programme>
        </parent>
        <relations>
          <categories>
            <category classification="collection" type="belongsTo">
              <language>en</language>
              <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
              <code>/legalbasis</code>
              <title>Legal Basis</title>
              <description>Programme: Legal basis for research funding</description>
              <displayCode>/Legal Basis</displayCode>
            </category>
            <category classification="source" type="isProvidedBy">
              <language>en</language>
              <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
              <code>/corda</code>
              <title>CORDA</title>
              <description>RTD research data warehouse</description>
              <displayCode>/CORDA</displayCode>
            </category>
          </categories>
        </relations>
      </programme>
      <programme type="relatedTopic" source="corda">
        <availableLanguages>en</availableLanguages>
        <rcn>706026</rcn>
        <id>HORIZON_HORIZON-EIC-2021-ACCELERATOROPEN-01</id>
        <code>HORIZON-EIC-2021-ACCELERATOROPEN-01</code>
        <frameworkProgramme>HORIZON</frameworkProgramme>
        <title>EIC Accelerator Open 2021</title>
        <parent>
          <programme>
            <rcn>20300</rcn>
            <code>HORIZON-Topics</code>
          </programme>
        </parent>
        <relations>
          <categories>
            <category classification="collection" type="belongsTo">
              <language>en</language>
              <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
              <code>/topic</code>
              <title>Topic</title>
              <description>Programme: Part of the Commission work programme implementing legal basis</description>
              <displayCode>/Topic</displayCode>
            </category>
            <category classification="source" type="isProvidedBy">
              <language>en</language>
              <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
              <code>/corda</code>
              <title>CORDA</title>
              <description>RTD research data warehouse</description>
              <displayCode>/CORDA</displayCode>
            </category>
            <category classification="topicKeyword" type="isAbout">
              <language>en</language>
              <availableLanguages>en</availableLanguages>
              <code>/43456234</code>
              <title>Project financing</title>
              <displayCode>/Project financing</displayCode>
            </category>
            <category classification="topicKeyword" type="isAbout">
              <language>en</language>
              <availableLanguages>en</availableLanguages>
              <code>/43454386</code>
              <title>Market-creating innovation</title>
              <displayCode>/Market-creating innovation</displayCode>
            </category>
            <category classification="topicKeyword" type="isAbout">
              <language>en</language>
              <availableLanguages>en</availableLanguages>
              <code>/43450539</code>
              <title>Competitor analysis</title>
              <displayCode>/Competitor analysis</displayCode>
            </category>
            <category classification="topicKeyword" type="isAbout">
              <language>en</language>
              <availableLanguages>en</availableLanguages>
              <code>/43450029</code>
              <title>Business model innovation</title>
              <displayCode>/Business model innovation</displayCode>
            </category>
            <category classification="topicKeyword" type="isAbout">
              <language>en</language>
              <availableLanguages>en</availableLanguages>
              <code>/43451698</code>
              <title>Entrepreneurship</title>
              <displayCode>/Entrepreneurship</displayCode>
            </category>
            <category classification="topicKeyword" type="isAbout">
              <language>en</language>
              <availableLanguages>en</availableLanguages>
              <code>/43453594</code>
              <title>Innovation support services</title>
              <displayCode>/Innovation support services</displayCode>
            </category>
            <category classification="topicKeyword" type="isAbout">
              <language>en</language>
              <availableLanguages>en</availableLanguages>
              <code>/43457773</code>
              <title>Spin-off companies</title>
              <displayCode>/Spin-off companies</displayCode>
            </category>
            <category classification="topicKeyword" type="isAbout">
              <language>en</language>
              <availableLanguages>en</availableLanguages>
              <code>/43456213</code>
              <title>Product innovation</title>
              <displayCode>/Product innovation</displayCode>
            </category>
            <category classification="topicKeyword" type="isAbout">
              <language>en</language>
              <availableLanguages>en</availableLanguages>
              <code>/43454395</code>
              <title>Marketing strategy</title>
              <displayCode>/Marketing strategy</displayCode>
            </category>
            <category classification="topicKeyword" type="isAbout">
              <language>en</language>
              <availableLanguages>en</availableLanguages>
              <code>/43453822</code>
              <title>Investment readiness</title>
              <displayCode>/Investment readiness</displayCode>
            </category>
            <category classification="topicKeyword" type="isAbout">
              <language>en</language>
              <availableLanguages>en</availableLanguages>
              <code>/43452043</code>
              <title>Feasibility analysis</title>
              <displayCode>/Feasibility analysis</displayCode>
            </category>
            <category classification="topicKeyword" type="isAbout">
              <language>en</language>
              <availableLanguages>en</availableLanguages>
              <code>/43458031</code>
              <title>Sustainable innovation</title>
              <displayCode>/Sustainable innovation</displayCode>
            </category>
            <category classification="topicKeyword" type="isAbout">
              <language>en</language>
              <availableLanguages>en</availableLanguages>
              <code>/43450041</code>
              <title>Business support services</title>
              <displayCode>/Business support services</displayCode>
            </category>
            <category classification="topicKeyword" type="isAbout">
              <language>en</language>
              <availableLanguages>en</availableLanguages>
              <code>/43458163</code>
              <title>Technological innovation</title>
              <displayCode>/Technological innovation</displayCode>
            </category>
            <category classification="topicKeyword" type="isAbout">
              <language>en</language>
              <availableLanguages>en</availableLanguages>
              <code>/43457365</code>
              <title>SME support</title>
              <displayCode>/SME support</displayCode>
            </category>
            <category classification="topicKeyword" type="isAbout">
              <language>en</language>
              <availableLanguages>en</availableLanguages>
              <code>/43456414</code>
              <title>Public sector innovation</title>
              <displayCode>/Public sector innovation</displayCode>
            </category>
            <category classification="topicKeyword" type="isAbout">
              <language>en</language>
              <availableLanguages>en</availableLanguages>
              <code>/43456186</code>
              <title>Private investment</title>
              <displayCode>/Private investment</displayCode>
            </category>
            <category classification="topicKeyword" type="isAbout">
              <language>en</language>
              <availableLanguages>en</availableLanguages>
              <code>/43453576</code>
              <title>Innovation management</title>
              <displayCode>/Innovation management</displayCode>
            </category>
            <category classification="topicKeyword" type="isAbout">
              <language>en</language>
              <availableLanguages>en</availableLanguages>
              <code>/43450521</code>
              <title>Company valuation</title>
              <displayCode>/Company valuation</displayCode>
            </category>
            <category classification="topicKeyword" type="isAbout">
              <language>en</language>
              <availableLanguages>en</availableLanguages>
              <code>/43452100</code>
              <title>Financial &amp; Investment management</title>
              <displayCode>/Financial &amp; Investment management</displayCode>
            </category>
            <category classification="topicKeyword" type="isAbout">
              <language>en</language>
              <availableLanguages>en</availableLanguages>
              <code>/43451181</code>
              <title>Due diligence</title>
              <displayCode>/Due diligence</displayCode>
            </category>
            <category classification="topicKeyword" type="isAbout">
              <language>en</language>
              <availableLanguages>en</availableLanguages>
              <code>/43451088</code>
              <title>Disruptive innovation</title>
              <displayCode>/Disruptive innovation</displayCode>
            </category>
            <category classification="topicKeyword" type="isAbout">
              <language>en</language>
              <availableLanguages>en</availableLanguages>
              <code>/43458202</code>
              <title>Technology management</title>
              <displayCode>/Technology management</displayCode>
            </category>
            <category classification="topicKeyword" type="isAbout">
              <language>en</language>
              <availableLanguages>en</availableLanguages>
              <code>/43450026</code>
              <title>Business management</title>
              <displayCode>/Business management</displayCode>
            </category>
            <category classification="topicKeyword" type="isAbout">
              <language>en</language>
              <availableLanguages>en</availableLanguages>
              <code>/43450017</code>
              <title>Business development</title>
              <displayCode>/Business development</displayCode>
            </category>
            <category classification="topicKeyword" type="isAbout">
              <language>en</language>
              <availableLanguages>en</availableLanguages>
              <code>/43457812</code>
              <title>Start-up companies</title>
              <displayCode>/Start-up companies</displayCode>
            </category>
            <category classification="topicKeyword" type="isAbout">
              <language>en</language>
              <availableLanguages>en</availableLanguages>
              <code>/43458661</code>
              <title>Venture capital</title>
              <displayCode>/Venture capital</displayCode>
            </category>
            <category classification="topicKeyword" type="isAbout">
              <language>en</language>
              <availableLanguages>en</availableLanguages>
              <code>/43450014</code>
              <title>Business coaching and mentoring</title>
              <displayCode>/Business coaching and mentoring</displayCode>
            </category>
            <category classification="topicKeyword" type="isAbout">
              <language>en</language>
              <availableLanguages>en</availableLanguages>
              <code>/43456756</code>
              <title>Risk management</title>
              <displayCode>/Risk management</displayCode>
            </category>
            <category classification="topicKeyword" type="isAbout">
              <language>en</language>
              <availableLanguages>en</availableLanguages>
              <code>/43453837</code>
              <title>IPR management</title>
              <displayCode>/IPR management</displayCode>
            </category>
          </categories>
        </relations>
      </programme>
      <result type="relatedResult" source="corda">
        <availableLanguages>en</availableLanguages>
        <rcn>922302</rcn>
        <id>190151672_PSHORIZON</id>
        <title>Periodic Reporting for period 2 - RESPIRE (Development of the first oral disease-modifying treatment for chronic obstructive pulmonary disease (COPD))</title>
        <description>periodic</description>
        <teaser>Palobiofarma is a Spanish clinical stage biotech company focused on discovering and developing innovative treatments that modulate adenosine receptors. Our lead compound, PBF-680, is being developed as a first-in-class, disease-modifying therapy for chronic obstructive...</teaser>
        <sourceUpdateDate>2024-11-27 14:02:58</sourceUpdateDate>
        <contentUpdateDate>2023-04-06 09:59:19</contentUpdateDate>
        <relations>
          <associations>
            <webItem type="relatedResultAttachment" source="corda">
              <language>en</language>
              <availableLanguages>en,any</availableLanguages>
              <uri>/docs/results/horizon/190151/190151672_PS/figure-2-medication-kits-pbf-680.jpg</uri>
              <alternativeText>Figure 2. Study design of the clinical trial in COPD patients.</alternativeText>
              <mimetype>image/jpeg</mimetype>
              <size>1517568</size>
            </webItem>
            <webItem type="relatedResultAttachment" source="corda">
              <language>en</language>
              <availableLanguages>en,any</availableLanguages>
              <uri>/docs/results/horizon/190151/190151672_PS/figure-1-study-design-in-copd-with-pbf-680.jpg</uri>
              <alternativeText>Figure 1. Medication kit of PBF-680 for the clinical trial “Respire”</alternativeText>
              <mimetype>image/jpeg</mimetype>
              <size>70656</size>
            </webItem>
            <webItem type="relatedResultAttachment" source="corda">
              <language>en</language>
              <availableLanguages>en,any</availableLanguages>
              <uri>/docs/results/horizon/190151/190151672_PS/figure-3-initiation-visit-in-sant-pau-hospital.jpg</uri>
              <alternativeText>Figure 3. Initiation visit of Respire clinical trial in Santa Creu i Sant Pau Hospital, Barcelona.</alternativeText>
              <mimetype>image/jpeg</mimetype>
              <size>407552</size>
            </webItem>
            <webItem type="relatedResultAttachment" source="corda">
              <language>en</language>
              <availableLanguages>en,any</availableLanguages>
              <uri>/docs/results/horizon/190151/190151672_PS/copd-study-pbf-680.jpg</uri>
              <alternativeText>Figure 4. COPD study primary outcome result</alternativeText>
              <mimetype>image/jpeg</mimetype>
              <size>109568</size>
            </webItem>
          </associations>
          <categories>
            <category classification="collection" type="belongsTo">
              <language>en</language>
              <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
              <code>/pubsum</code>
              <title>Report Summary</title>
              <description>Result: Publishable summary (FP7 SESAM) and Summary for publication (H2020 SyGMa)</description>
              <displayCode>/Report Summary</displayCode>
            </category>
            <category classification="source" type="isProvidedBy">
              <language>en</language>
              <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
              <code>/corda</code>
              <title>CORDA</title>
              <description>RTD research data warehouse</description>
              <displayCode>/CORDA</displayCode>
            </category>
          </categories>
        </relations>
      </result>
    </associations>
    <categories>
      <category classification="collection" type="belongsTo">
        <language>en</language>
        <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
        <code>/project</code>
        <title>Project</title>
        <description>Project factsheets</description>
        <displayCode>/Project</displayCode>
      </category>
      <category classification="euroSciVoc" type="isInFieldOfScience">
        <language>en</language>
        <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
        <code>/21/35/155/22184243</code>
        <title>autoimmune diseases</title>
        <displayCode>/medical and health sciences/basic medicine/immunology/autoimmune diseases</displayCode>
      </category>
      <category classification="euroSciVoc" type="isInFieldOfScience">
        <language>en</language>
        <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
        <code>/21/33/121/44109686/8132740</code>
        <title>coronaviruses</title>
        <displayCode>/medical and health sciences/health sciences/infectious diseases/RNA viruses/coronaviruses</displayCode>
      </category>
      <category classification="euroSciVoc" type="isInFieldOfScience">
        <language>en</language>
        <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
        <code>/21/39/225</code>
        <title>oncology</title>
        <displayCode>/medical and health sciences/clinical medicine/oncology</displayCode>
      </category>
      <category classification="policyPriorities" type="marker" weight="0">
        <language>en</language>
        <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
        <code>/digitalAgenda</code>
        <title>Digital agenda</title>
        <description>This tracker monitors Horizon Europe’s financial contribution to the development of digital technologies and the digitisation of the economy and society (known as ‘Digital transition’).</description>
        <displayCode>/Digital agenda</displayCode>
      </category>
      <category classification="policyPriorities" type="marker" weight="0">
        <language>en</language>
        <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
        <code>/cleanAir</code>
        <title>Clean air</title>
        <description>This tracker monitors the Horizon Europe’s financial contribution to the clean air policy (National Emission Ceiling Directive) aiming to improve ambient air quality and tackle air pollution, to protect the environment and human health.</description>
        <displayCode>/Clean air</displayCode>
      </category>
      <category classification="policyPriorities" type="marker" weight="0">
        <language>en</language>
        <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
        <code>/ai</code>
        <title>Artificial intelligence</title>
        <description>This tracker monitors Horizon Europe’s financial contribution to the development and deployment of AI-based technologies and solutions. Projects that develop AI-tools as part of their research method are included</description>
        <displayCode>/Artificial intelligence</displayCode>
      </category>
      <category classification="policyPriorities" type="marker" weight="0">
        <language>en</language>
        <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
        <code>/climate</code>
        <title>Climate action</title>
        <description>This tracker monitors the Horizon Europe’s financial contribution to both mitigating climate change (e.g., contributions to the reduction of greenhouse gas emissions) and adapting to climate change by building resilience (e.g., regarding floods, droughts, spatial planning and better governance, adaptation to changing climate in value chains, etc.).</description>
        <displayCode>/Climate action</displayCode>
      </category>
      <category classification="policyPriorities" type="marker" weight="0">
        <language>en</language>
        <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
        <code>/biodiversity</code>
        <title>Biodiversity</title>
        <description>This tracker monitors the Horizon Europe’s financial contribution to Europe’s biodiversity’s path to recovery including species protection, ecosystem conservation, and habitat rehabilitation, all essential for resilience in climate adaptation and addressing ecosystem services but also environmental crime and the health-environment connection.</description>
        <displayCode>/Biodiversity</displayCode>
      </category>
      <category classification="projectFundingSchemeCategory" type="relatedProjectFundingSchemeCategory">
        <language>en</language>
        <availableLanguages>en</availableLanguages>
        <code>/HORIZON-EIC-ACC-BF</code>
        <title>HORIZON EIC Accelerator Blended Finance</title>
        <description>HORIZON EIC Accelerator Blended Finance</description>
        <displayCode>/HORIZON EIC Accelerator Blended Finance</displayCode>
      </category>
      <category classification="source" type="isProvidedBy">
        <language>en</language>
        <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
        <code>/corda</code>
        <title>CORDA</title>
        <description>RTD research data warehouse</description>
        <displayCode>/CORDA</displayCode>
      </category>
    </categories>
  </relations>
</project>